1. Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.
- Author
-
Cui N, Li S, Zhang Y, Yin F, Chen X, Luo Z, Wan S, Li X, Kong L, and Wang X
- Subjects
- Animals, Mice, Phosphorylation, Structure-Activity Relationship, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors chemistry, Receptor-Interacting Protein Serine-Threonine Kinases metabolism, Apoptosis, Protein Kinases metabolism
- Abstract
Receptor-interacting protein kinase 1 (RIPK1), a vital protein of the necroptosis pathway, plays a pivotal role in various inflammatory diseases. Sibiriline has been reported to be a potent ATP-competitive RIPK1 inhibitor, but its anti-necroptotic effects are limited. A series of structural analogues of Sibiriline were synthesized and evaluated for their anti-necroptotic activity. Comprehensive structure-activity relationship (SAR) was performed to left azaindole and right substituents of benzene of Sibiriline, respectively. The optimal compound KWCN-41, specifically inhibiting cell necroptosis but not apoptosis, protects cell survival by blocking the necroptotic pathway, which inhibits the phosphorylation of essential proteins of the necroptosis. It also prevented the development of inflammation and reduced the level of inflammatory factors in mice. KWCN-41 is expected to be a lead compound for further studies in inflammatory diseases., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF